Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
parp2 siRNA
- Development stage
- Preclinical
- Lead developer
- Inserm
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
PARP2 siRNA is a small interfering RNA (siRNA) designed to silence the expression of the Poly(ADP-ribose) polymerase 2 (PARP2) gene. In preclinical research, it is utilized as a molecular tool to investigate the role of PARP2 in DNA repair pathways and cell survival. Studies have demonstrated that silencing PARP2 can mimic the chemosensitizing and pro-apoptotic effects of chemical PARP inhibitors in various cancer models, including non-small cell lung cancer (NSCLC), mesothelioma, and ovarian cancer. By reducing PARP2 protein levels, this siRNA impairs the cell's ability to repair DNA damage, thereby promoting apoptosis via the intrinsic pathway, particularly in cells exhibiting PARP overactivation.
- Other names
- PARP2-specific siRNAPARP-2-specific siRNAPARP 2-specific siRNAsiRNA targeting PARP2
02
Targets
PARP2 (Poly (adp-ribose) polymerase 2)Pol II (RNA polymerase II elongation factors)
Beyond the preview
Go deeper on parp2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on parp2 siRNA.